Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 CR rates between DNMT3A R882 mutation and wild type patients after one or two cycles of induction based on different regimen

From: Influence of DNMT3A R882 mutations on AML prognosis determined by the allele ratio in Chinese patients

Induction cycles Anthracyclines Total
CR/n (%)
R882 wild-type
CR/n (%)
R882 mutation
CR/n (%)
OR (95% CI) P value
First cycle Aclarubicin 95/187 (50.80) 92/173 (53.18) 3/14 (21.43) 4.165 (1.122–15.451) 0.022
Daunorubicin 28/84 (33.33) 27/78 (34.62) 1/6 (16.67) 2.647 (0.294–23.821) 0.653
Idarubicin 90/203 (44.33) 83/183 (45.35) 7/20 (35.00) 1.541 (0.589–4.041) 0.376
Mitoxantrone 114/287 (39.72) 107/264 (40.53) 7/23 (30.43) 1.558 (0.620–3.915) 0.343
Pirarubicin 21/74 (28.38) 20/69 (28.99) 1/5 (20.00) 1.633 (0.172–15.524) 1.000
First or second cycle Aclarubicin 243/379 (64.12) 229/349 (65.62) 14/30 (46.67) 2.181 (1.030–4.619) 0.038
  1. CR complete response, R882 arginine 882, OR odds ratio, CI confidence interval
  2. Italic values indicate significance of P value (P < 0.05)